Detalhe da pesquisa
1.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Ann Hematol
; 102(6): 1501-1511, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088816
2.
Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients.
Neoplasma
; 69(2): 412-424, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35037760
3.
Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.
Int J Mol Sci
; 23(23)2022 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36499093
4.
Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Br J Haematol
; 195(1): 95-107, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34500493
5.
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience.
Ann Hematol
; 100(10): 2541-2546, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34309714
6.
Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant.
Neoplasma
; 68(3): 519-527, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33618517
7.
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
J Clin Oncol
; 41(7): 1383-1392, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36315921
8.
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
Biomedicines
; 10(10)2022 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36289797
9.
LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients.
Biomedicines
; 9(11)2021 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34829867